The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome.
New York City, United States. In Nat Genet, 09 Dec 2015
Mutation analysis identified a broad spectrum of somatic mutations in key genes involved in epigenetic regulation (TET2, CREBBP, KMT2D (MLL2), KMT2C (MLL3), BRD9, SMARCA4 and CHD3) and signaling, including MAPK1, BRAF, CARD11 and PRKG1 mutations driving increased MAPK, NF-κB and NFAT activity upon T cell receptor stimulation.
Genomic Alterations in Langerhans Cell Histiocytosis.
Boston, United States. In Hematol Oncol Clin North Am, 31 Oct 2015
Most of the abnormalities described to date affect the RAS/RAF/MEK/extracellular-signal-regulated kinase (ERK) pathway: more than 50% of LCH cases carry activating mutations in BRAF, whereas another 10% to 28% carry activating mutations of MAP2K1, which encodes MEK1.
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road.
Cambridge, United Kingdom. In Nat Rev Cancer, 24 Oct 2015
The role of the ERK signalling pathway in cancer is thought to be most prominent in tumours in which mutations in the receptor tyrosine kinases RAS, BRAF, CRAF, MEK1 or MEK2 drive growth factor-independent ERK1 and ERK2 activation and thence inappropriate cell proliferation and survival.